Fwd: World of MS Update Service

[Guest guest]

World of MS Update ServiceResearch News====================Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and incidence--------------------This epidemiological study demonstrates a prevalence of multiple sclerosis of 163.6 affected individuals per 100,000 inhabitants in a county of central Norway. A trend for an increasing incidence is noted.http://www.msif.org/goemail.rm?id=267Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new Mc criteria.--------------------A comparison of Mc and Poser diagnostic criteria performance is carried out in a group of 76 people with “suspected†multiple sclerosis. Addition of Poser’s criteria category “laboratory definite multiple sclerosis†to “clinically definite†increased the number of people that can be diagnosed with multiple sclerosis over and above Mc’s criteria category “multiple sclerosisâ€.http://www.msif.org/goemail.rm?id=268Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple treated with cladribine--------------------In this study levels of two different chemokines are measured in cerebrospinal fluid and blood of patients with multiple sclerosis. The results suggest that cladribine interacts specifically with some components of the chemokine system.http://www.msif.org/goemail.rm?id=269Clinical efficacy of gabapentin for paroxysmal symptoms in multiple sclerosis--------------------The results of this open-label study suggest that gabapentin might of benefit to treat paroxysmal symptoms in patients with MS. Among symptoms treated were paresthesia/dysesthesia, trigeminal neuralgia, painful tonic spasms and episodic itching.http://www.msif.org/goemail.rm?id=270Gene-expression profiling of the early stages of MOG-induced EAE proves EAE-resistance as an active process--------------------This study tries to identify genes responsible for resistance to the animal model of multiple sclerosis.http://www.msif.org/goemail.rm?id=271Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage.--------------------Inducible nitric oxide synthase (iNOS) is an enzyme that produces nitric oxide (NO) which has been shown to be a damage mediator in multiple sclerosis (MS). This paper reports on the levels of iNOS and its exact location within lesions of multiple sclerosis.http://www.msif.org/goemail.rm?id=272TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation--------------------VCAM-1 is an adhesion molecule which is crucial for the entrance of immune cells into the central nervous sytem. This paper shows that VCAM-1 is produced not only by cells of the blood vessels but also by astrocytes, and that this latter production is enhanced through tumor necrosis factor receptor-1 pathways.http://www.msif.org/goemail.rm?id=273Corticosteroid resistance in a subpopulation of multiple sclerosis patients as measured by ex vivo dexamethasone inhibition of LPS induced IL-6 production--------------------This study shows that people with multiple sclerosis might be resistant to the immunosuppressant effects of corticosteroids.http://www.msif.org/goemail.rm?id=274Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis--------------------Pixantrone is an antineoplastic drug with similar beneficial effects but better risk profile than mitoxantrone. This paper shows that, as mitoxantrone, it is also effective to decreae the severity of the animal model of multiple sclerosis.http://www.msif.org/goemail.rm?id=275Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis--------------------This study reports on encouraging results with a new form of administration of interferon beta tested in animals.http://www.msif.org/goemail.rm?id=276Anticipation of age at onset in multiple sclerosis: a Sardinian cohort study.--------------------In the well-studied Sardinian population, age at onset of multiple sclerosis seems to be decreasing over generations. The reasons for this trend are discussed.http://www.msif.org/goemail.rm?id=277A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts--------------------The authors investigate the possible implication of the pathogen Chlamydia pneumoniae in the development of multiple sclerosis in two different cohorts from the United States of America.http://www.msif.org/goemail.rm?id=278Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta--------------------The results of this open-label before-after phase II clinical trial are encouraging. Combination therapy of daclizumab plus interferon beta is shown to significantly reduce the number of gadolinium-enhancing lesions in patients who did not respond to stand-alone interferon beta treatment.http://www.msif.org/goemail.rm?id=279Association of protein kinase C alpha (PRKCA) gene with multiple sclerosis in a UK population--------------------The gene encoding for protein kinase C alpha (PRKCA) is located, among other genes, in a genomic region linked to an increased risk of multiple sclerosis. The results of this genetic study show that variations in the gene encoding for PRKCA are associated with an increased risk of multiple sclerosis and warrant further investigation of the role of PRKCA in the pathogenesis of multiple sclerosis.http://www.msif.org/goemail.rm?id=280Health effects of dental amalgam exposure: a retrospective cohort study.--------------------The results of this study are reassuring as only borderline evidence of an association between amalgam fillings and risk of multiple sclerosis is found.http://www.msif.org/goemail.rm?id=281Brain Plasticity in Multiple Sclerosis.--------------------An editorial dealing with the issue of cortical reorganization as a means to overide brain damage and prevent functional loss in patients with multiple sclerosis.NO ABSTRACT AVAILABLE.http://www.msif.org/goemail.rm?id=282----------------------------------------Thank you for using the World of MS update service that is provided by the Multiple Sclerosis International Federation (MSIF).MSIF presents, in this user friendly format, the latest MS research findings published within medical and scientific journals.However MSIF is not able to validate or be held responsible for this research, nor can MSIF comment on its accuracy or relevance.The 'Research News' section on the World of MS website is generously funded by the UK MS Society and is compiled with the support of theInstitute of Neurology, University College, London, UK.*Please do not reply to this email*If you have any queries about the site or the Update Service please contact us at info@...

World of MS Update Service, 01 Jun 2004

====================

World of MS Update Service

Research News

====================

Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and

incidence

--------------------

This epidemiological study demonstrates a prevalence of multiple sclerosis

of 163.6 affected individuals per 100,000 inhabitants in a county of

central Norway. A trend for an increasing incidence is noted.

http://www.msif.org/goemail.rm?id=267

Diagnosis of multiple sclerosis: comparison of the Poser criteria and the

new Mc criteria.

--------------------

A comparison of Mc and Poser diagnostic criteria performance is

carried out in a group of 76 people with “suspected†multiple sclerosis.

Addition of Poser’s criteria category “laboratory definite multiple

sclerosis†to “clinically definite†increased the number of people that

can

be diagnosed with multiple sclerosis over and above Mc’s criteria

category “multiple sclerosisâ€.

http://www.msif.org/goemail.rm?id=268

Interleukin-8 and RANTES levels in patients with relapsing-remitting

multiple treated with cladribine

--------------------

In this study levels of two different chemokines are measured in

cerebrospinal fluid and blood of patients with multiple sclerosis. The

results suggest that cladribine interacts specifically with some components

of the chemokine system.

http://www.msif.org/goemail.rm?id=269

Clinical efficacy of gabapentin for paroxysmal symptoms in multiple

sclerosis

--------------------

The results of this open-label study suggest that gabapentin might of

benefit to treat paroxysmal symptoms in patients with MS. Among symptoms

treated were paresthesia/dysesthesia, trigeminal neuralgia, painful tonic

spasms and episodic itching.

http://www.msif.org/goemail.rm?id=270

Gene-expression profiling of the early stages of MOG-induced EAE proves

EAE-resistance as an active process

--------------------

This study tries to identify genes responsible for resistance to the animal

model of multiple sclerosis.

http://www.msif.org/goemail.rm?id=271

Inducible nitric oxide synthase in chronic active multiple sclerosis

plaques: distribution, cellular expression and association with myelin

damage.

--------------------

Inducible nitric oxide synthase (iNOS) is an enzyme that produces nitric

oxide (NO) which has been shown to be a damage mediator in multiple

sclerosis (MS). This paper reports on the levels of iNOS and its exact

location within lesions of multiple sclerosis.

http://www.msif.org/goemail.rm?id=272

TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to

destructive inflammation

--------------------

VCAM-1 is an adhesion molecule which is crucial for the entrance of immune

cells into the central nervous sytem. This paper shows that VCAM-1 is

produced not only by cells of the blood vessels but also by astrocytes, and

that this latter production is enhanced through tumor necrosis factor

receptor-1 pathways.

http://www.msif.org/goemail.rm?id=273

Corticosteroid resistance in a subpopulation of multiple sclerosis patients

as measured by ex vivo dexamethasone inhibition of LPS induced IL-6

production

--------------------

This study shows that people with multiple sclerosis might be resistant to

the immunosuppressant effects of corticosteroids.

http://www.msif.org/goemail.rm?id=274

Pixantrone (BBR2778) reduces the severity of experimental allergic

encephalomyelitis

--------------------

Pixantrone is an antineoplastic drug with similar beneficial effects but

better risk profile than mitoxantrone. This paper shows that, as

mitoxantrone, it is also effective to decreae the severity of the animal

model of multiple sclerosis.

http://www.msif.org/goemail.rm?id=275

Intranasal administration of interferon beta bypasses the blood-brain

barrier to target the central nervous system and cervical lymph nodes: a

non-invasive treatment strategy for multiple sclerosis

--------------------

This study reports on encouraging results with a new form of administration

of interferon beta tested in animals.

http://www.msif.org/goemail.rm?id=276

Anticipation of age at onset in multiple sclerosis: a Sardinian cohort

study.

--------------------

In the well-studied Sardinian population, age at onset of multiple

sclerosis seems to be decreasing over generations. The reasons for this

trend are discussed.

http://www.msif.org/goemail.rm?id=277

A prospective study of Chlamydia pneumoniae infection and risk of MS in two

US cohorts

--------------------

The authors investigate the possible implication of the pathogen Chlamydia

pneumoniae in the development of multiple sclerosis in two different

cohorts from the United States of America.

http://www.msif.org/goemail.rm?id=278

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple

sclerosis patients failing to respond to interferon beta

--------------------

The results of this open-label before-after phase II clinical trial are

encouraging. Combination therapy of daclizumab plus interferon beta is

shown to significantly reduce the number of gadolinium-enhancing lesions in

patients who did not respond to stand-alone interferon beta treatment.

http://www.msif.org/goemail.rm?id=279

Association of protein kinase C alpha (PRKCA) gene with multiple sclerosis

in a UK population

--------------------

The gene encoding for protein kinase C alpha (PRKCA) is located, among

other genes, in a genomic region linked to an increased risk of multiple

sclerosis. The results of this genetic study show that variations in the

gene encoding for PRKCA are associated with an increased risk of multiple

sclerosis and warrant further investigation of the role of PRKCA in the

pathogenesis of multiple sclerosis.

http://www.msif.org/goemail.rm?id=280

Health effects of dental amalgam exposure: a retrospective cohort study.

--------------------

The results of this study are reassuring as only borderline evidence of an

association between amalgam fillings and risk of multiple sclerosis is

found.

http://www.msif.org/goemail.rm?id=281

Brain Plasticity in Multiple Sclerosis.

--------------------

An editorial dealing with the issue of cortical reorganization as a means

to overide brain damage and prevent functional loss in patients with

multiple sclerosis.

NO ABSTRACT AVAILABLE.

http://www.msif.org/goemail.rm?id=282

----------------------------------------

Thank you for using the World of MS update service that is provided by the

Multiple Sclerosis International Federation (MSIF).

MSIF presents, in this user friendly format, the latest MS research

findings published within medical and scientific journals.

However MSIF is not able to validate or be held responsible for this

research, nor can MSIF comment on its accuracy or relevance.

The 'Research News' section on the World of MS website is generously funded

by the UK MS Society and is compiled with the support of the

Institute of Neurology, University College, London, UK.

*Please do not reply to this email*

If you have any queries about the site or the Update Service please contact

us at info@...

To unsubscribe or edit your profile/details/subscription please go to:

http://www.msif.org/applications/people_profiles/

[Guest guest]

World of MS Update Service, 08 Jun 2004====================World of MS Update ServiceResearch News====================Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis--------------------A review focusing on the impact of neutralising antibodies on the therapeutic efficacy of interferon beta. The article also deals with the management of antibody-positive patients.http://www.msif.org/goemail.rm?id=323Cell-based remyelinating therapies in multiple sclerosis: evidence from experimental studies--------------------This review focuses on new strategies to promote central nervous system remyelination.http://www.msif.org/goemail.rm?id=324Health outcomes in multiple sclerosis--------------------A review of cost-effectiveness studies of interferon beta in patients with multiple sclerosis.http://www.msif.org/goemail.rm?id=325Microvascular Abnormality in Relapsing-Remitting Multiple Sclerosis: Perfusion MR Imaging Findings in Normal-appearing White Matter--------------------A magnetic resonance-based study showing changes in blood circulation in areas of normal-appearing brain tissue in patients with multiple sclerosis.http://www.msif.org/goemail.rm?id=326Parent-of-origin effect in multiple sclerosis: observations in half-siblings--------------------The present article assesses the risk of multiple sclerosis among offspring of affected parents. The risk is significantly higher if the affected parent is the mother.http://www.msif.org/goemail.rm?id=327Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis--------------------Nitric oxide synthase (NOS) is an enzyme that produces nitric oxide (NO), which has been shown to be a damage mediator in multiple sclerosis (MS). This study concludes that variations in the gene coding for this enzyme modify susceptibility to multiple sclerosis.http://www.msif.org/goemail.rm?id=328Multiple Sclerosis - Editorial--------------------Editorial for this month's supplement of the journal Multiple Sclerosis. This issue is almost entirely devoted to primary progressive multiple sclerosis. At the end of most articles in this issue you will find enlightening debates among international experts in the field.**NO ABSTRACT AVAILABLE**http://www.msif.org/goemail.rm?id=329Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis--------------------A review of the different clinical aspects of primary progressive multiple sclerosis with especial emphasis on the diagnosis of the condition.http://www.msif.org/goemail.rm?id=330Natural history of primary progressive multiple sclerosis--------------------Results from the London (Ontario) cohort natural history study are reviewed in this article. The author focuses on the primary progressive subgroup of patients.http://www.msif.org/goemail.rm?id=331Immunologic factors in primary progressive multiple sclerosis--------------------This paper presents a review of immunological aspects of multiple sclerosis. The authors focus on the possible differences to be found in the primary progressive form of the condition.http://www.msif.org/goemail.rm?id=332The pathology of primary progressive multiple sclerosis--------------------The authors of this review on the pathological aspects of multiple sclerosis focus on the possible differences between primary progressive multiple sclerosis and the other clinical courses of multiple sclerosis.http://www.msif.org/goemail.rm?id=333Primary progressive multiple sclerosis: cerebrospinal fluid considerations--------------------This paper focuses on the usefulness of the analysis of cerebrospinal fluid in patients with multiple sclerosis.http://www.msif.org/goemail.rm?id=334Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques--------------------A review on the neuroradiological aspects of primary progressive multiple sclerosis. The authors focus on the factors that might help explain the clinico-radiological paradox observed in patients with primary progressive multiple sclerosis.http://www.msif.org/goemail.rm?id=335Effect of drugs in secondary disease progression in patients with multiple sclerosis--------------------A review on the different therapeutic options available for patients with secondary progressive multiple sclerosis.http://www.msif.org/goemail.rm?id=336Overview of London trial of intramuscular interferon-beta 1a in primary-progressive multiple sclerosis--------------------A summary of the results of the clinical trial of intramuscular interferon beta 1a in patients with primary progressive multiple sclerosis carried out in London (United Kingdom).http://www.msif.org/goemail.rm?id=337Mitoxantrone as a potential therapy for primary progressive multiple sclerosis--------------------Information on an ongoing trial of mitoxantrone in patients with primary progressive multiple sclerosis is given in this article.http://www.msif.org/goemail.rm?id=338Overview of European pilot study of interferon beta 1b in primary progressive multiple sclerosis--------------------A summary of the results of the clinical trial of subcutaneous interferon beta 1b in patients with primary progressive multiple sclerosis carried out in Barcelona.http://www.msif.org/goemail.rm?id=339The PROMiSe trial: baseline data review and progress report--------------------Some clinical and radiological findings obtained from the cohort of 943 patients involved in the multinational, multicentre, double-blind, placebo-controlled trial of glatiramer acetate in patients with primary progressive multiple sclerosis (PROMISE trial).http://www.msif.org/goemail.rm?id=340Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis--------------------A subgroup of patients from the PROMISE trial (multinational, multicentre, double-blind, placebo-controlled trial of glatiramer acetate in patients with primary progressive multiple sclerosis) were involved in this multicentre study of proton magnetic resonance spectroscopy. The authors report on the baseline findings.http://www.msif.org/goemail.rm?id=341On the horizon: possible neuroprotective role for glatiramer acetate--------------------This review deals with evidence supporting the hypothesis of a possible neuroprotective effect of glatiramer acetate in multiple sclerosis.http://www.msif.org/goemail.rm?id=342----------------------------------------Thank you for using the World of MS update service that is provided by the Multiple Sclerosis International Federation (MSIF).MSIF presents, in this user friendly format, the latest MS research findings published within medical and scientific journals.However MSIF is not able to validate or be held responsible for this research, nor can MSIF comment on its accuracy or relevance.The 'Research News' section on the World of MS website is generously funded by the UK MS Society and is compiled with the support of theInstitute of Neurology, University College, London, UK.*Please do not reply to this email*If you have any queries about the site or the Update Service please contact us at info@...

World of MS Update Service, 08 Jun 2004

====================

World of MS Update Service

Research News

====================

Neutralizing antibodies to interferon beta: implications for the management

of multiple sclerosis

--------------------

A review focusing on the impact of neutralising antibodies on the

therapeutic efficacy of interferon beta. The article also deals with the

management of antibody-positive patients.

http://www.msif.org/goemail.rm?id=323

Cell-based remyelinating therapies in multiple sclerosis: evidence from

experimental studies

--------------------

This review focuses on new strategies to promote central nervous system

remyelination.

http://www.msif.org/goemail.rm?id=324

Health outcomes in multiple sclerosis

--------------------

A review of cost-effectiveness studies of interferon beta in patients with

multiple sclerosis.

http://www.msif.org/goemail.rm?id=325

Microvascular Abnormality in Relapsing-Remitting Multiple Sclerosis:

Perfusion MR Imaging Findings in Normal-appearing White Matter

--------------------

A magnetic resonance-based study showing changes in blood circulation in

areas of normal-appearing brain tissue in patients with multiple sclerosis.

http://www.msif.org/goemail.rm?id=326

Parent-of-origin effect in multiple sclerosis: observations in half-siblings

--------------------

The present article assesses the risk of multiple sclerosis among offspring

of affected parents. The risk is significantly higher if the affected

parent is the mother.

http://www.msif.org/goemail.rm?id=327

Linkage and association with the NOS2A locus on chromosome 17q11 in

multiple sclerosis

--------------------

Nitric oxide synthase (NOS) is an enzyme that produces nitric oxide (NO),

which has been shown to be a damage mediator in multiple sclerosis (MS).

This study concludes that variations in the gene coding for this enzyme

modify susceptibility to multiple sclerosis.

http://www.msif.org/goemail.rm?id=328

Multiple Sclerosis - Editorial

--------------------

Editorial for this month's supplement of the journal Multiple Sclerosis.

This issue is almost entirely devoted to primary progressive multiple

sclerosis. At the end of most articles in this issue you will find

enlightening debates among international experts in the field.

**NO ABSTRACT AVAILABLE**

http://www.msif.org/goemail.rm?id=329

Overview of primary progressive multiple sclerosis (PPMS): similarities and

differences from other forms of MS, diagnostic criteria, pros and cons of

progressive diagnosis

--------------------

A review of the different clinical aspects of primary progressive multiple

sclerosis with especial emphasis on the diagnosis of the condition.

http://www.msif.org/goemail.rm?id=330

Natural history of primary progressive multiple sclerosis

--------------------

Results from the London (Ontario) cohort natural history study are reviewed

in this article. The author focuses on the primary progressive subgroup of

patients.

http://www.msif.org/goemail.rm?id=331

Immunologic factors in primary progressive multiple sclerosis

--------------------

This paper presents a review of immunological aspects of multiple

sclerosis. The authors focus on the possible differences to be found in the

primary progressive form of the condition.

http://www.msif.org/goemail.rm?id=332

The pathology of primary progressive multiple sclerosis

--------------------

The authors of this review on the pathological aspects of multiple

sclerosis focus on the possible differences between primary progressive

multiple sclerosis and the other clinical courses of multiple sclerosis.

http://www.msif.org/goemail.rm?id=333

Primary progressive multiple sclerosis: cerebrospinal fluid considerations

--------------------

This paper focuses on the usefulness of the analysis of cerebrospinal fluid

in patients with multiple sclerosis.

http://www.msif.org/goemail.rm?id=334

Imaging primary progressive multiple sclerosis: the contribution of

structural, metabolic, and functional MRI techniques

--------------------

A review on the neuroradiological aspects of primary progressive multiple

sclerosis. The authors focus on the factors that might help explain the

clinico-radiological paradox observed in patients with primary progressive

multiple sclerosis.

http://www.msif.org/goemail.rm?id=335

Effect of drugs in secondary disease progression in patients with multiple

sclerosis

--------------------

A review on the different therapeutic options available for patients with

secondary progressive multiple sclerosis.

http://www.msif.org/goemail.rm?id=336

Overview of London trial of intramuscular interferon-beta 1a in

primary-progressive multiple sclerosis

--------------------

A summary of the results of the clinical trial of intramuscular interferon

beta 1a in patients with primary progressive multiple sclerosis carried out

in London (United Kingdom).

http://www.msif.org/goemail.rm?id=337

Mitoxantrone as a potential therapy for primary progressive multiple

sclerosis

--------------------

Information on an ongoing trial of mitoxantrone in patients with primary

progressive multiple sclerosis is given in this article.

http://www.msif.org/goemail.rm?id=338

Overview of European pilot study of interferon beta 1b in primary

progressive multiple sclerosis

--------------------

A summary of the results of the clinical trial of subcutaneous interferon

beta 1b in patients with primary progressive multiple sclerosis carried out

in Barcelona.

http://www.msif.org/goemail.rm?id=339

The PROMiSe trial: baseline data review and progress report

--------------------

Some clinical and radiological findings obtained from the cohort of 943

patients involved in the multinational, multicentre, double-blind,

placebo-controlled trial of glatiramer acetate in patients with primary

progressive multiple sclerosis (PROMISE trial).

http://www.msif.org/goemail.rm?id=340

Multicentre proton magnetic resonance spectroscopy imaging of primary

progressive multiple sclerosis

--------------------

A subgroup of patients from the PROMISE trial (multinational, multicentre,

double-blind, placebo-controlled trial of glatiramer acetate in patients

with primary progressive multiple sclerosis) were involved in this

multicentre study of proton magnetic resonance spectroscopy. The authors

report on the baseline findings.

http://www.msif.org/goemail.rm?id=341

On the horizon: possible neuroprotective role for glatiramer acetate

--------------------

This review deals with evidence supporting the hypothesis of a possible

neuroprotective effect of glatiramer acetate in multiple sclerosis.

http://www.msif.org/goemail.rm?id=342

----------------------------------------

Thank you for using the World of MS update service that is provided by the

Multiple Sclerosis International Federation (MSIF).

MSIF presents, in this user friendly format, the latest MS research

findings published within medical and scientific journals.

However MSIF is not able to validate or be held responsible for this

research, nor can MSIF comment on its accuracy or relevance.

The 'Research News' section on the World of MS website is generously funded

by the UK MS Society and is compiled with the support of the

Institute of Neurology, University College, London, UK.

*Please do not reply to this email*

If you have any queries about the site or the Update Service please contact

us at info@...

To unsubscribe or edit your profile/details/subscription please go to:

http://www.msif.org/applications/people_profiles/